Aims/hypothesis. The gene encoding the β 3 -subunit (GPIIIa) of the platelet α 2 β 3 -integrin (fibrinogen receptor) shows a polymorphism PlA1/A2 with the A2 allele putatively associated with an increased risk of acute ischaemic events. This study investigated whether Type 2 diabetes as a particular macrovascular risk factor associates with the thrombogenic PIA2 genotype. Methods. The PlA genotype was determined in 112 consecutive Type 2 diabetic patients additionally classified according to the presence of macrovascular disease. Forty-four non-diabetic patients with angiografically documented cardiovascular disease (CAD/ AMI) and a further 59 non-diabetic subjects with no angiografical signs of CAD were investigated as genomic background control (n=103). PIA-genotyping was carried out by standard restriction fragment length analysis (RFLA) of PCR amplified lymphocyte template DNA. Results. The overall allelic PlA2-prevalence accounted to 34.8% (39/112) in diabetic patients as compared to 14.6% (15/103) in non-diabetic patients [OR 3.1 (1.6-6.1), p<0.01].This odds ratio increased to 7.0 (2.5-19.7), (p<0.01) in subjects free of criteria of macrovascular disease. In non-diabetic control subjects without CAD there was an allelic PIA2 frequency of 10.2% (6/59) as compared to 20.5% (9/44) in patients with CAD and a history of AMI being less than either diabetes subgroup. The PIA2 prevalence in the subgroup of diabetes patients with macrovascular complications did not differ from the respective value in patients without macrovascular disease. [29.0% (20/69) vs. 44.2% (19/43)]. Conclusion/interpretation. This study confirms a trendwise association of PlA2 with severe coronary artery disease, but rather suggests an even stronger, highly significant association with the metabolic condition of Type 2 diabetes mellitus. This justifies the speculation that pathways dependent on the platelet α 2 β 3 integrin physiology could be implicated in the pathogenesis of Type 2 diabetes which lends further support to the "common soil" hypothesis of diabetes and vascular disease. [Diabetologia (2003) Abbreviations: AMI, acute myocardial infarction; CAD, coronary artery disease; GPIIIa, β 3 subunit of the platelet surface α 2 β 3 -integrin (GPIIb-IIIa, fibrinogen-receptor); PIA, platelet antigen; RGD, aminoacidsequence Arg-Gly-Asp; SNP, single nucleotide polymorphism. Diabetologia (2003) 46:984-989 
Acute ischaemic coronary events continue to be the major cause of death in Type 2 diabetes [1] . Type 2 diabetes per se qualifies for the same risk as having experienced a first myocardial infarction [2, 3] . The clinical ischaemia cascade of acute coronary syndromes is clearly a platelet-driven phenomenon [4] . Consequently, increased numbers of platelets circulate in an activated state in diabetic patients [5, 6] . Increases in the constitutive number of platelet surface fibrinogen receptors (GPIIb-IIIa) led us to assume a primary "diabetic" thrombocytopathy which renders the peripheral platelet pool more susceptible towards activation [7] .
The nucleated bone marrow megakaryocytes have been shown to be altered both in terms of DNA content (ploidy) and quantitative GPIIb-IIIa expression in the diabetic BB-rat model and in human Type 2 diabetes patients [8, 9] .
The platelet GPIIb-IIIa receptor converges the wide array of agonist-induced activation signalling towards functional platelet aggregation by fibrinogen crossbridging ("final common pathway"; [10] ). The outside-in signalling cascade of this receptor is modulated by the proteolytic enzyme calpain, an isoform of which has shown a genetic polymorphism with tight association to the manifestation of clinical Type 2 diabetes mellitus [16) .The gene encoding the β 3 -subunit (GPIIIa) of the receptor which contains the RGD-recognizing sequence of the fibrinogen molecule, shows a polymorphism (PlA1/A1, PIA1/A2, PIA2/A2) suggested to promote more intense platelet-fibrinogenreceptor interaction [11, 12] . Clinically, others have reported for the first time the existence of a strong association between the genomic prevalence of the PlA2 allele and acute coronary thrombosis [13] .
Along with the reported findings of DNA-changes in the nucleated megakaryocytic precursor cells under diabetic conditions, we found it intriguing to investigate whether genomic variation also exists in the GPIIb-IIIa gene in favour of the putative thrombogenic PlA2 allele and how the vascular status is related in diabetic patients as compared to a genetic control background.
Subjects and methods
Study design and patients. This investigation was designed as a cross-sectional study including consecutive patients with diabetes mellitus and non-diabetic control subjects. All investigations were carried out in accordance with the Declaration of Helsinki as revised in 2000.
Blood samples from a total of 215 subjects were analyzed. The diagnosis of diabetes required documented hyperglycaemia and increased HbA 1 . The type of diabetes was classified according to mode of treatment, anamnesis and clinical case presentation using recent American Diabetes Association guidelines [14] . In the diabetes group (n=112), patients of the German Diabetes Research Institute, Duesseldorf with (n=69) or without clinically apparent macrovascular complications (n=43) were included. Macrovascular disease was assumed with the presence of symptoms (stenocardia, gangrene, amputation or confirmed apoplexia), angiologically proven atherosclerotic disease (peripheral, cerebral or coronary arteries), ischaemic ECG signs (ST-segment depression ≥1 mV) and the requirement of any targeting medication (e.g. nitrates). Endpoint reporting was based on recalling patient data, detailed review of hospital records using standard criteria and the recent clinical investigation.
The control group consisted of non-diabetic patients (n=103) admitted to the cardiological department of the University Clinic Essen with unspecified chestpain where CAD was excluded (n=59) or confirmed on the basis of coronary angiography and a proven history of AMI (n=44) ( Table 1) .
PlA-genotyping. The genotype (PIA1/A1, PIA1/A2, PIA2/A2) was determined by restriction fragment length analysis (RFLA).
Genomic DNA was isolated from whole blood samples using the QIAamp Blood Kit (Qiagen, Hilden, Germany) according to the manufacturers protocol. The samples were stored at −20°C in EDTA (1.6 mg/ml) coated collection tubes (Sarstedt, Nümbrecht, Germany). Exon two was amplified using the flanking primers 5′-TTC TGA TTG CTG GAC TTC TCT T-3′(sense)/ 5′TCT CTC CCC ATG GCA AAG AGT-3′(antisense). The PCR was done for 32 cycles (92°C 30 s; 55°C 1 min; 72°C 1 min.) with a final extension at 72°C for 10 min (Hybraid-Omnigen-PCR, MWG-Biotech, Ebersberg, Germany). The amplification mix (40 µl) contained 100 ng of template DNA, 1.5 mmol/l MgCl 2 , 200 µmol of each dNTP, 2.5 pmol of each primer, 1-times PCR-reaction buffer [20 mmol/l Tris-HCl (pH 8,4), 50 mmol/l KCl] and 25 mU/µl Taq-polymerase, both from Gibco-Life Technologies, (Eggenstein, Germany). The resulting PCR product (266 base-pairs) was further analysed by restriction analysis:
The mutation characterizing the PIA2-allele is a substitution of cytosine for thymidine at position 1565, AC EMBL J05427 , in exon two of the platelet fibrinogen receptor on chromosome 17 [15] . Carrying this substitution the exon two PCR-amplificate (266 bp) can be restricted by Nci I (5′-CC 1565 ↓(C/G)GG-3′) creating two restriction fragments of 216 and 50 bp respectively and by Msp I (5′-C↓C 1565 GG-3′) resulting in three restriction fragments of 171, 50, 45 bp (enzymes from MBI-Fermentas, St. Leon-Rot, Germany). The wild-type allele PIA1 is not cut by Nci I and only cut one time by Msp I giving two fragments of 216 and 50 bp. The restrictions were carried out overnight according to the manufacturers protocol. The resulting fragments were concentrated using 1/10 volume sodium acetate (3 mol, pH 5.2) and 2.5 volume ethanol (100%) for 12 h at −20°C. DNA was collected (15,000 g, 4°C, 30 min) and redisolved in 5 µl H 2 O autoclaved . 3 µl of loading buffer [5% (v/v) glycerol, 0.04% (w/v) bromphenolblue and 0.04% (w/v) xylenxyanol] were added and the restriction pattern was analysed in a 2% agarose gel (1×TAE) containing ethidium bromide (0,5 µg/ml).
SSCP-analysis and fluorescence sequencing of the PCRamplificates and digest products was done by spot checks and achieved complete confirmation.
Clinical chemistry. All documentation parameters (HbA 1 , cholesterol, LDL-, HDL-cholesterol, fibrinogen) were determined using routine methods. 
Results
Risk factor profile. There were slight, yet significant differences between the groups in the prevalence of hypertension, age and HDL cholesterol (Table 1) . When comparing patient subgroups, fibrinogen was additionally increased in diabetic patients with macrovascular complications. There were no statistically definite associations of selected risk factors and PIA-genotype (data not shown).
Genotyping. The prevalence of the PlA2 allele (PlAX/A2: either heterozygous PlA1/A2 or homozygous PlA2/A2) among the diabetic patients accounts for 34.8% (39/112) being more than two-fold higher than among non-diabetic control subjects [14.6%; 15/103; OR 3.1 (1.6-6.1), p<0.01] (Fig. 1A,B) .
Subgroup comparison of Type 2 diabetes patients without vascular complications with non-diabetic control subjects without documented coronary artery disease resulted in an even greater separation of PlA2-allele-positivity: 44.2% (19/43) compared with 10.2% (6/59); OR 7.0 (2.5-19.7), p<0.01.
Multivariate analysis. The magnitude of the reported odds ratios did only slightly change after multivariate adjustment for sex, age and BMI (data set complete with 10 dropouts because of missing values): OR 3.6 (1.7-7.5), and OR 12.9 (3.8-43.2), (p<0.01, p<0.01) (Fig. 1A) .
Vascular disease. In contrast, the separation was lost when exclusively comparing the Type 2 diabetic patients with vascular disease with the non-diabetic control subjects with documented coronary artery disease: 29.0% (20/69) compared with 20.5% (9/44); OR 1.6 (0.6-3.9), [OR adjusted: 1.3 (0.5-3.8)].
CAD/AMI patients without diabetes show a twofold higher PlA2 carriage (20.5%; 9/44) than subjects without CAD (10.2%; 6/59). In the Type 2 diabetes group there was no difference in the prevalence of PlA2 whether vascular complications were detectable (29.0%; 20/69) or not (44,2%, 19/43) (Fig. 1B) . 
Discussion
We report a higher prevalence of the PIA2-allele of the gene encoding for the GPIIIa (β 3 ) subunit of the platelet surface α 2 β 3 -integrin (GPIIb-IIIa) in patients with Type 2 diabetes mellitus as compared to non-diabetic control subjects. The association of this single nucleotide polymorphism (SNP) was strong with the metabolic disease, but absent with the manifestation of clinical atherosclerotic disease.
This represents an unexpected new finding for Type 2 diabetes patients being at a particular high risk for the development of coronary artery disease. Our cross-sectional linkage analysis with clinical phenomenology clearly provides no causative relationship. However, similar to the association of genetic variations in the calpain-10 gene our finding here suggests that platelet pathways not yet considered may be of some pathogenetic impact for the metabolic disease or inherently belong to the wide array of pathophysiologic alterations linked to Type 2 diabetes [16] . Agonistdependent calpain activation is recognized as part of the outside-in stimulus response pathways being implicated in the procoagulant activity of activated platelets [17] . Recently, this enzyme has been shown to proteolyse structural and signalling proteins involved in cytoskeleton remodelling and platelet activation events downstream to α 2 β 3 -integrin (GPIIb-IIIa) activation [18, 19] . Unfortunately, we do not have parallel genomic calpain data available in this limited cohort study, but our results of a tight genetic association of the α 2 β 3 -integrin (GPIIb-IIIa) physiology (not exclusively restricted to platelets) with Type 2 diabetes could provide an additional pathway as to how genetic variations in the calpain system might functionally operate. Moreover, an interaction of both genetic variations could be anticipated, but the nature of this remains completely speculative.
We cannot provide genomic linkage data of the investigated SNP with other genetic variations in close proximity of the PlA2 gene locus (17q21.32). GLUT-4 and the glucagon-receptor are known Type 2 diabetes related genes, but both are located at the opposite end of the chromosome (17p13; 17q25) suggesting no interaction with the SNP under investigation.
Based on antibody binding data it is assumed that the PIA2-genotype is processed into functionally relevant phenotypical alterations of ligand (fibrinogen)-receptor (GPIIb-IIIa) interaction possibly causing hyperaggregation in response to stimulating agonists such as shear, matrix components or coagulation inducers [20, 21, 22, 23, 24] . Clearly, PIA2-carriers generate more thrombin after microvascular trauma which underlines the functional meaning of this particular platelet SNP also suggesting some pharmagenomic importance [25, 26] . A more complex interpretation can be derived from the data from another study showing that ligation of the PIA2-genotype integrin could affect outside-in signalling efficacy with the consequence of more intense platelet-platelet interaction, but also increased adherence to immobilized adhesion molecules. Such events might take place not only in the large high flow vessels, but also in the nutritive microcirculation being regulatory part of the skeletal muscle energy metabolism [27, 28] .
Our data further promulgate the earlier suggestion of a primary, genetically-determined link between diabetes and platelet physiology which could operate via the GPIIb-IIIa platelet surface integrin. This receptor was phenotypically shown to be increased on platelets from diabetic patients, but in the BB-rat model of insulin deficient diabetes increased GPIIb-IIIa-expression was also accompanied by changes in DNA-content (ploidy) of the nucleated megakaryocytic bone marrow precursor cells [9] . It was therefore consequent to ask for genetic prothrombotic variants associated with platelet hyper-reactivity in Type 2 diabetic patients. The unequivocally clear answer from our data shows that the PIA2-positive genotype is closely associated with the diagnosis of diabetes suggesting a possible relationship with the metabolic disease itself. It is tempting to speculate therefore, that the PIA-SNP belongs to the diabetes-related genetic variation which also operates lineage-specific blood cell lines [29, 30] . The PIA2-type megakaryocyte-platelet axis could then result in a highly reactive peripheral platelet pool which responds to lower activation thresholds ("activated megakaryocyte-platelet-system" [7] ).
In non-diabetic patients our data support the assumption of a possible association with the risk of acute ischaemic coronary syndromes trendwise by the observed doubling in the allelic frequency: 10.2 compared with 20.5% (non significant). Increased PIA2-prevalence in CAD and in patients after myocardial infarction was reported [31, 32, 33, 34, 35] . In a prospective nested case control trial within the Physician's Health Study no association was found of the PIA2-prevalence with any thrombotic endpoint at all and this was confirmed by the ECTIM and ARIC studies and by some smaller studies [36, 37, 38, 39, 40] . Others seem to resolve these striking differences by their suggestion that PIA2-prevalence does not act as a risk factor per se, but strongly determines the thrombogenic reactivity of the circulating platelets [32] . This concept is attractive, since it addresses platelet hyperreactivity super-imposed to coronary atherosclerosis to act as the final mechanism which translates risk factor-dependent vessel wall morphology into blood-dependent thrombotic infarction. It is interesting to note that no interference must be anticipated with the newly-recognized myocardial infarction susceptibility gene on chromosome 14 [41] . However, a relation between PIA2-prevalence and cholesterol levels as well as with smoking upon ischaemic endpoints was reported clearly suggesting an interaction between the genotype and environmental factors [42, 43] . In turn, prevalence of diabetes could have contributed skewness to the clinical and epidemiological studies mentioned above thus accounting for some of the contradictory results.
The magnitude of our observation might depend on the unexpected low PIA2-prevalence in the non-diabetic control subjects which potentially reflects a high selection bias with this special population of chest pain patients. However, the increase of the PIA2-prevalence above 30%, exceeding the ranges observed with CAD, and a history of myocardial infarction in simple association with the presence of Type 2 diabetes fits with earlier observations. One study found a PIA2-prevalence up to 38% in Type 2 diabetic patients with macrovascular disease before the age of 60 being not significantly different from 29% in patients without macrovascular disease [43] .
In summary, our cross-sectional analysis suggests a close association of the PIA2 SNP with Type 2 diabetes mellitus. The nature of this association cannot be answered by this limited data set, but the view that a prothrombotic genetic variation associates with the metabolic disease further supports the "common soil" hypothesis: that the presence of the PIA2 allele could precipitate thrombotic endpoints, explaining in part the extraordinary risk of these patients for acute ischaemic events. Thus, we propose PIA2 SNP as a diabetes related genetic variation being secondarily involved in the macrovascular prognosis of such patients. However, this hypothesis urgently awaits confirmation from the prospective epidemiological KORA trial data.
